



Robust Candidates for Language Development and Evolution Are Significantly Dysregulated in the Blood of People With Williams Syndrome

Antonio Benítez-Burraco1* and Ryo Kimura2

¹ Department of Spanish, Linguistics, and Theory of Literature (Linguistics), Faculty of Philology, University of Seville, Seville, Spain, ² Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

OPEN ACCESS

Edited by:

Robin Clark, University of Pennsylvania, United States

Reviewed by:

Alfredo Ardila, Florida International University, United States Marco Smolla, University of Pennsylvania, United States

*Correspondence:

Antonio Benítez-Burraco abenitez8@us.es

Specialty section:

This article was submitted to Social and Evolutionary Neuroscience, a section of the journal Frontiers in Neuroscience

Received: 10 January 2019 Accepted: 05 March 2019 Published: 26 March 2019

Citation:

Benitez-Burraco A and Kimura R (2019) Robust Candidates for Language Development and Evolution Are Significantly Dysregulated in the Blood of People With Williams Syndrome. Front. Neurosci. 13:258. doi: 10.3389/fnins.2019.00258 Williams syndrome (WS) is a clinical condition, involving cognitive deficits and an uneven language profile, which has been the object of intense inquiry over the last decades. Although WS results from the hemideletion of around two dozen genes in chromosome 7, no gene has yet been probed to account for, or contribute significantly to, the language problems exhibited by the affected people. In this paper we have relied on gene expression profiles in the peripheral blood of WS patients obtained by microarray analysis and show that several robust candidates for language disorders and/or for language evolution in the species, all of them located outside the hemideleted region, are up- or downregulated in the blood of subjects with WS. Most of these genes play a role in the development and functional anomalies in people with this condition. Overall, these genes emerge as robust candidates for language dysfunction in WS.

Keywords: Williams syndrome, blood transcriptional profile, language disorders, language evolution, candidate genes

INTRODUCTION

Williams syndrome (WS) is a clinical condition resulting from a hemizygous deletion of 1.5 to 1.8 Mb on 7q11.23, which encompasses nearly 30 genes (Korenberg et al., 2000; Pober et al., 2010). The affected people exhibit a distinctive behavioral and cognitive profile, with enhanced sociability, mental retardation, impaired spatial cognition, and spared musical abilities (Reilly et al., 1990; Udwin and Yule, 1991; Bellugi et al., 1999; Galaburda et al., 2002; Levitin et al., 2005). Language abilities are significantly preserved in people with WS compared to other neurodevelopmental disorders, to the extent that this syndrome has often been used to support the view that language can be teased apart from other aspects of cognition. Nonetheless, recent, fine-grained analyses of WS language have concluded that WS language is delayed or impaired across different levels compared to the neurotypical population (Karmiloff-Smith and Mills, 2006; Brock, 2007; Mervis and Becerra, 2007; Martens et al., 2008 for good reviews). Specifically, children with WS experience problems with irregular word forms and complex syntax; likewise, they have problems with word definitions,

1

although they usually excel on expressive vocabulary (including semantic organization and fluency) (Volterra et al., 1996; Mervis et al., 1999; Purser et al., 2011; Van Den Heuvel et al., 2016; see Mervis and Becerra, 2007 for discussion). However, as with other aspects of the cognitive profile of this condition, no robust gene-to-phenotype associations have been established in the language domain. To date, the most promising candidates for language dysfunction in WS are GTF2I, BAZ1B, and LIMK1. In particular, GTF2I, which encodes a regulator of transcription, has been repeatedly related to the behavioral and cognitive disabilities that are typically found in this condition and that have an impact on language function (Morris et al., 2003; Tassabehji et al., 2005; Sakurai et al., 2011; Hoeft et al., 2014). Its adjacent paralog, GTF2IRD1, has been related to altered vocalizations among other features (Howard et al., 2012). Interestingly too, BAZ1B haploinsufficiency explains almost 50% of transcriptional dysregulation in WS neurons, with BAZ1B target genes being enriched in functions related to neurogenesis and neuron differentiation (Lalli et al., 2016). Regarding LIMK1, it regulates synaptic plasticity and long-term memory (Todorovski et al., 2015), and its hemideletion has been hypothesized to account for the observed deficits in spatial cognition in combination with other genes (Gray et al., 2006; Smith et al., 2009). Still, these potential links with aspects of language (dys)function seem quite vague, particularly if one considers our remarkable understanding of the genetic underpinnings of human language, language disorders, and language evolution (see Scharff and White, 2004; Li and Bartlett, 2012; Benítez-Burraco, 2013; Graham et al., 2015; Fisher, 2017; Murphy and Benítez-Burraco, 2017, 2018 for reviews). Examining how robust candidate genes for language disorders and language evolution behave in people with WS should help refine our view of the molecular causes of the language deficits attested in this condition. One general reason supporting this approach is the deep link that exists between evolution and (abnormal) development, in the spirit of evo-devo theories. One specific reason supporting this approach is that although in WS the number of hemideleted genes is small, changes in the dosage of hundreds, or even thousands, of other genes can be expected, with a potential impact on language abilities, in the spirit of omnigenic theories of complex diseases (Boyle et al., 2017; Peedicavil and Grayson, 2018). Recently Kimura et al. (2018) confirmed that the dysregulation of several co-expression modules involving dozens of genes outside of the 7q11.23 region seemingly accounts for the complex phenotypes observed in WS patients. Importantly, they found BCL11A, a gene associated with speech disorders, among the hub genes in the top WS-related modules.

In this paper we have conducted a more focused research on the potential dysregulation of genes related to language outside the WS region as a possible explanation of the distinctive language profile of the affected people. Similarly to Kimura et al. (2018), we have relied on gene expression profiles in peripheral blood of WS patients obtained by microarray analysis. We have found that significant differences exist in the blood of subjects with WS compared to neurotypical controls in the expression levels of robust candidates for language development, language evolution, and language impairment.

METHODS

The list of core candidates for language (abnormal) development and language evolution (Supplementary Table S1) encompasses two subsets of genes. The first subset consists of strong candidates for language disorders, in particular, developmental dvslexia (DD) and specific language disorder (SLI), as listed by Paracchini et al. (2016), Pettigrew et al. (2016) and Chen et al. (2017). The second subset consists of strong candidates for language evolution, as compiled by Boeckx and Benítez-Burraco (2014a,b) and Benítez-Burraco and Boeckx (2015). These are genes involved in the globularization of the human skull/brain and the cognitive changes accounting for our species-specific ability to learn and use languages (aka our language- readiness). Overall, the genes comprising this second subset fulfill several criteria. First, they have changed (and/or interact with genes that have changed) after our split from Neanderthals/Denisovans, including changes in their coding regions and/or their epigenetic profile. Second, they play some known role in brain development, regionalization, wiring, and/or function. Third, they are candidates for language dysfunction in broad cognitive disorders, particularly, autism spectrum disorder (ASD) and schizophrenia (SZ) (see Benítez-Burraco and Murphy, 2016; Murphy and Benítez-Burraco, 2016, 2017 for details about their role in language processing).

The gene expression profiling data of peripheral blood were obtained from our previous study (Kimura et al., 2018), available at the Gene Expression Omnibus (GSE89594). Briefly, total RNA from 32 WS patients and 30 healthy controls were analyzed using an Agilent Human GE v2 8×60K Microarray (Agilent Technologies). After the normalization step, differentially expressed genes (DEG) were calculated using the Limma R package (Smyth, 2005). The Benjamini-Hochberg method was used to evaluate the false discovery rate (FDR) (Benjamini and Hochberg, 1995). DEG were defined as FDR < 0.05 and the |fold change (FC)| > 1.2. Gene list enrichment analysis was performed using Fisher's exact test. All the expressed genes were used as the background gene list.

RESULTS

We found that candidates for language (abnormal) development and language evolution are significantly dysregulated in the blood of subjects with WS (p = 1.1e-7 by Fisher's exact test). **Figure 1** shows the genes that are significantly up- or down-regulated compared to controls (FDR < 0.05, |FC| > 1.2).

In order to check the specificity of this set of genes in relation to language we conducted a functional enrichment analysis with Enrichr (amp.pharm.mssm.edu/Enrichr; Chen et al., 2013; Kuleshov et al., 2016), which showed that they are significantly related to biological processes, molecular functions, and abnormal phenotypes of interest for language (**Table 1**).



FIGURE 1 Genes significantly dysregulated in the blood of subjects with WS (FDR < 0.05, |FC| > 1.2). Candidate genes for language disorders (SLI, DD) are displayed in light red, whereas candidates for language evolution are colored in light blue.

Finally, these genes were predicted to be preferentially expressed in body parts important for language processing or for language development, particularly, the cerebellum and the thalamus (**Table 1** and **Supplementary Table S2**). We now provide a detailed discussion of our results.

DISCUSSION

Functional Characterization of Individual Genes

Nearly one third of the language-related genes found downregulated in the blood of subjects with WS are candidates for DD (*DOCK4*, *ZNF385D*, and *CEP63*) and/or for SLI (*DOCK4*, *NFXL1*). As other members of the Dock family, DOCK4 regulates cytoskeleton assembly and cell adhesion and migration (Gadea and Blangy, 2014). Specifically, DOCK4 has been shown to

be involved in neuronal migration and neurite differentiation (Ueda et al., 2008; Xiao et al., 2013), via interaction with the actin-binding protein cortactin (Ueda et al., 2013). Knockdown of Dock4 in mice abolishes commissural axon attraction by Shh (Makihara et al., 2018). The gene has been related to neuronal migration and neurite outgrowth anomalies linked to DD (Shao et al., 2016), although it is also associated with ASD (Pagnamenta et al., 2010) and SZ (Alkelai et al., 2012). GWAs have associated markers in ZNF385D to the co-occurrence of reading disability and language impairment (Eicher et al., 2013), but also to negative symptoms in SZ (Xu et al., 2013). CEP63 is required for normal spindle assembly, being involved in maintaining centriole number and establishing the order of events in centriole formation (Brown et al., 2013). Besides its association with DD (Einarsdottir et al., 2015), the gene is also a candidate for primary microcephaly (Marjanović et al., 2015), a feature that is commonly found in subjects with WS (Jernigan and Bellugi, 1990; TABLE 1 | Functional enrichment analysis according to Enrichr of the set of genes significantly dysregulated in the blood of subjects with WS.

IndexNamePeralePeraleZeronResContractContractContractPeraleRegulation of match spindle discipation (CO-1900054)0.0047010.04600-0.3.470.04701PeraleRegulation of match spindle discipation (CO-19000540)0.0018980.04600-0.3.470.04701PeraleRegulation of match cal cycle(CO-051147)0.0018980.04000-0.3140.04701PeraleRegulation of match cal cycle(CO-051147)0.0018980.04000-0.3140.04701PeraleRegulation of match cal cycle(CO-051147)0.0018280.04000-2.3130.04701PeraleRegulation of match as protein (SO-001825)0.0018280.04000-2.3130.04001PeraleRegulation of match as protein (SO-0012017)0.0017210.0017210.01732-2.0141.0180PeraleRegulation of match as protein (SO-0012017)0.0017710.00771-2.0141.0181PeraleMark hases brotein (SO-000354)0.0017410.001720.0271-2.0141.0181PeraleMark hases brotein (SO-000354)0.0017710.007710.0271-2.0141.0181PeraleName frame fra				Adjusted	Combined	
Biological Process 2018 Image Mathematics In Standball and Production (GO-20001844) 0.0041781 0.04409 -3.77 19.88 1 Pregulation of motole since indexpont (GO-1005094) 0.004193 0.04409 -3.87 17.74 3 Preather regulation of motole since indexpont (GO-1005084) 0.004193 0.04409 -3.47 17.74 4 Negaliave motole and event preating (GO-00014411) 0.006182 0.04409 -2.48 17.49 6 Environic unamers preasy motopogonesis (GO-000255) 0.047181 0.04609 -2.38 14.20 7 Attachment of Elevation to protein GO-000255) 0.047181 0.04609 -2.31 14.20 10 Mackenmal end differentiation (GO-000262) 0.005682 0.04609 -2.31 14.20 11 MAP Insues broadprease stative (GO-00070122) 0.00774 0.07352 -3.07 16.41 12 MAP Insues broadprease stative (GO-00070122) 0.00774 0.07352 -2.10 10.052 14 MAP Insues broadprease stative (GO-00070122) 0.00774 0.07352 -2.10 10.052	Index	Name	P-value	p-value	Z-score	score
1 Regulation of matics open (0.00050) 0.04498	GO Biolo	gical Process 2018				
9 Regulation of machine sprudie in divergence (100-190356) 0.04690 -4.57 19.44 4 Negative regulation of variable mechanism (050-0506) 0.04690 -2.81 17.59 5 Positive regulation of variable mechanism (50-004893) 0.04690 -2.81 17.49 6 Enthorino carriaor type dive methop(2008 65:004893) 0.046191 0.04690 -2.81 14.28 7 Attractment of DP anchor to protein (0.0101696) 0.004791 0.04600 -2.81 14.29 8 Regulation of manulo task (0.00101601) 0.001282 0.04600 -2.81 14.20 10 More finate phosphatase activity (50.0017017) 0.004791 0.04792 -2.81 10.21 2 MA ² finase phosphatase activity (50.00017017) 0.03752 -2.30 11.51 10.22 3 Tartiszeption compressor briefly (50.000524) 0.007491 0.07452 -2.31 10.22 4 Institution (50.0005052) 0.007471 0.07452 -2.31 10.22 5 Institution finate monorine phosphatase activity (50.0001713) 0.02671	1	Regulation of endothelial cell chemotaxis to fibroblast growth factor (GO:2000544)	0.004791	0.04609	-3.72	19.88
3 Positive regulation of wacular andorhalia call profession (Go.1005547) 0.004698 0.04609 -2.47 17.44 5 Positive regulation of smooth made call migration (Go.0014911) 0.004693 0.04603 -2.48 17.49 6 Entropent carmen type age morphogenesis (GO.005409) 0.041731 0.04609 -2.98 16.34 7 Attamment of El instruct to polite (GO.005405) 0.001732 0.04609 -2.13 14.28 9 Poglation of Marches politeriatin (GO.107022) 0.005868 0.04609 -2.11 14.28 10 Mesoderms and ifferentiation (GO.0004838) 0.005868 0.04609 -2.11 16.41 2 MAP kinase typinainedimethytening hosphatase activity (GO.0017017) 0.004791 0.04752 -2.64 11.51 3 Tancorphonocenetros troning GO.0002520 0.002671 0.02752 -2.18 11.62 1 MAP kinase typinainedimethytening (GO.000271) 0.04791 0.02871 -2.28 8.03 1 Insuli-Mag gowth factor funding (GO.000271) 0.04827 0.07352 -2.18 10.27	2	Regulation of mitotic spindle checkpoint (GO:1903504)	0.004193	0.04609	-3.57	19.54
4 Nagiske regulation of macio cell register (GO 001401) 0.04602 2.8 17.88 6 Endryonic camue-type eye morphogenesis (GO 001401) 0.04602 2.85 16.34 7 Attachment of GPI andre to proke (GO 0014255) 0.04603 2.85 16.34 8 Regulation of macebility (GO 0014255) 0.04609 2.81 14.30 9 Regulation of macebility (GO 0014255) 0.04690 2.81 14.30 10 Macomeanic all differentity (GO 0017017) 0.04791 0.04795 2.84 18.31 70 MAP kinase prosephates extinty (GO 0003250) 0.004791 0.07352 -2.84 18.31 8 marker prosephates extinty (GO 0003221) 0.007714 0.07352 -2.8 10.02 8 reguter hyerine kinase broker proker hyerine kinase broker hyerine kinase bro	3	Positive regulation of vascular endothelial cell proliferation (GO: 1905564)	0.005985	0.04609	-3.47	17.74
5 Peakiev engulation of smooth muscle call migration (GO.0044911) 0.00682 0.006493 -0.48 16.44 7 Attachment of GPI anchor to protein (GO.0016256) 0.004791 0.04699 -2.98 16.48 7 Attachment of GPI anchor to protein (GO.0016255) 0.0001228 0.04609 -2.81 14.20 8 Regulation of MAP intake activity (GO.004400) 0.000585 0.04059 -2.71 18.37 10 Meacdemut and affireminitarin (GO.0016253) 0.000585 0.07352 -2.64 18.51 11 MAP insase tyrosine/senine/throsine/phosphatase activity (GO.00171717) 0.000376 0.07352 -2.61 11.51 12 MAP insase tyrosine/senine/throsine/file/GO.0005220 0.000377 0.07352 -2.61 11.52 13 Insulf-like growth factor binding (GO.000022) 0.010370 0.020371 -2.69 9.64 14 Insulf-like growth factor binding (GO.0000271) 0.020371 0.02271 -2.71 17.67 15 Insulf-like growth factor binding (GO.0000271) 0.01037 0.00271 -2.28 9.36 <	4	Negative regulation of meiotic cell cycle (GO:0051447)	0.004193	0.04609	-3.21	17.58
6 Entropycing carrenar-typen aye morphogenesia (CiO.004826) 0.004133 0.04039 -2.98 15.76 8 Regulation of MAP kinase activity (GO.0017405) 0.006522 0.04039 -2.83 14.20 9 Regulation of mucrobast proferention (GC: 190268). 0.006582 0.04039 -2.83 14.20 70 Maxed science and cid dimensitian (GO.20148333) 0.005682 0.04732 -2.41 13.87 70 MAP kinase phosphatase activity (GO.0017017) 0.007471 0.07352 -2.41 15.13 71 Transcription compressor binding (GO.200522) 0.006870 0.07352 -2.41 10.27 81 Insulf-like growth factor binding (GO.2007122) 0.01549 0.028771 -2.23 10.12 91 Insulf-like growth factor binding (GO.2007122) 0.01549 0.02871 -2.23 8.80 92 Prophyticitansi kinase activity (GO.2007124) 0.02871 -2.23 8.80 93 Prophyticitansi kinase activity (GO.2007124) 0.02871 -2.33 8.80 94 Prophyticitansi kinase activity (GO.2007174)	5	Positive regulation of smooth muscle cell migration (GO:0014911)	0.006582	0.04609	-3.48	17.49
7 Attachment of QPI anchor to protein (GO.0016265) 0.004761 0.004761 0.04690 -2.65 14.26 8 Regulation of Maruboast proteination (GO.0016262) 0.006682 0.04609 -2.81 14.20 10 Meacdemail and at differentiation (GO.0016333) 0.0005862 0.04609 -2.81 14.20 11 MAP kinase prosene/sene/theration prosphatase activity (GO.001721) 0.000781 0.07532 -2.61 18.41 2 MAP kinase prosene/sene/theration prosphatase activity (GO.000722) 0.000771 0.000752 -2.81 11.61 4 Insulf-like growth factor binding (GO.000520) 0.000897 0.07372 -2.81 11.02 6 Protein tyroaine kinase binding (GO.000722) 0.01444 0.008271 -2.28 8.80 9 Protein tyroaine kinase binding (GO.000721) 0.01372 0.02271 -2.84 7.83 7 Taramorption congrowth factor binding (GO.000721) 0.02374 0.02271 -2.84 7.83 8 Peotephrotiopineate binding (GO.000721) 0.02374 0.02371 -2.84 7.83 <td>6</td> <td>Embryonic camera-type eye morphogenesis (GO:0048596)</td> <td>0.004193</td> <td>0.04609</td> <td>-2.98</td> <td>16.34</td>	6	Embryonic camera-type eye morphogenesis (GO:0048596)	0.004193	0.04609	-2.98	16.34
8 Regulation of MAP kinase activity (00:004406) 0.001288 0.04609 -2.13 14.20 90 Regulation of max001ser profiferation (60:0004833) 0.005882 0.04609 -2.71 13.87 GO Molecular Function 2018 Unconservation 2018 0.005895 0.0732 -2.04 13.81 1 MAP kinase prosinesem thine prosphatase activity (G0:0017017) 0.004791 0.07352 -2.48 13.81 2 MAP kinase prosinesem torbing (G0:000520) 0.006965 0.07352 -2.10 10.02 3 Insum-like growth factor binding (G0:000520) 0.008670 0.028271 -2.29 9.84 4 insum-like growth factor binding (G0:000722) 0.008770 0.02871 -2.29 9.84 9 Posphatolytinosofic hindes (G0:000721) 0.01370 0.08271 -2.28 9.84 9 Posphatolytinosofic hindes (G0:000722) 0.00377 0.0271 -1.84 7.83 10 Fibribiast growth factor binding (G0:000730) 0.00371 0.008271 -2.29 9.84 11 Specific granuke (G0:0006320)<	7	Attachment of GPI anchor to protein (GO:0016255)	0.004791	0.04609	-2.95	15.76
9 Regulation for nuroblast proferation (GO:004833) 0.006582 0.04669 -2.81 13.87 00 MAP kinase prosiners/entertmonine phosphatase activity (GO:0017017) 0.007911 0.07582 -2.64 13.81 1 MAP kinase prosiners/entertmonine phosphatase activity (GO:0017017) 0.007741 0.07582 -2.64 13.51 3 Transcription corespressor binding (GO:0003220) 0.007744 0.07582 -2.18 10.27 6 Insulin-kie growth factor binding (GO:0003290) 0.008965 0.07582 -2.18 10.27 6 Protein tyrosine kinase binding (GO:0003297) 0.02910 0.02871 -2.29 8.48 7 Transcription cottor tor binding (GO:0001212) 0.0197 0.02871 -2.28 8.89 9 Prosphats//monotor kinase extivity (GO:0017134) 0.0197 0.02871 -2.28 8.89 9 Prosphats//monotor kinase extivity (GO:0007124) 0.03977 0.02871 -2.48 7.80 6 Mesotor tor binding (GO:00030971) 0.0397 0.02871 -1.54 4.80 7	8	Regulation of MAP kinase activity (GO:0043405)	0.001228	0.04609	-2.13	14.28
10 Mesodermi and all differentiation (GC.00.043333) 0.005985 0.04609 -2.71 13.87 GO Molecular Function 2015 -2.71 13.87 GO Molecular Function 2015 -3.07 16.41 2 MAP kinase bytosinderiserine threonine phosphatase activity (GC.0033549) 0.005965 0.07562 -2.38 115.66 4 insulin-like growth factor binding (GC.0001520) 0.008970 0.07852 -2.18 10.27 5 insulin-like growth factor binding (GC.0001521) 0.008970 0.08271 -2.28 9.84 8 Receptor tyrosine kinase activity (GC.000971) 0.01543 0.08271 -2.28 9.84 9 Prosphathylineosit kinase activity (GC.000574) 0.0372 0.08271 -2.28 9.84 0 Fiboobast growth factor binding (GC.000574) 0.0384 0.2061 -1.87 7.47 2 Spindie pole (GC.0000922) 0.00171 0.06824 0.2081 -1.43 4.40 4 Nucleuka (GC.00005730) 0.06824 0.2081 -1.43 4.40 <tr< td=""><td>9</td><td>Regulation of neuroblast proliferation (GO: 1902692)</td><td>0.006582</td><td>0.04609</td><td>-2.83</td><td>14.20</td></tr<>	9	Regulation of neuroblast proliferation (GO: 1902692)	0.006582	0.04609	-2.83	14.20
BO More investive interventive interventinterventive interventive interventive interventive in	10	Mesodermal cell differentiation (GO:0048333)	0.005985	0.04609	-2.71	13.87
1 MAP kinase prosine/serient/recenine phosphatese activity (GO.0003721) 0.007362 -3.07 16.41 2 MAP kinase phosphatese activity (GO.0003549) 0.005895 0.07352 -2.43 11.51 4 Insulin-like growth factor binding (GO.0001227) 0.008670 0.07352 -2.18 10.27 5 Insulin-like growth factor binding (GO.0001221) 0.01549 0.008271 -2.29 9.84 6 Protein tyrosine kinase binding (GO.0003271) 0.01549 0.008271 -2.29 9.84 7 Tarscription conjector binding (GO.00032712) 0.0172 0.08271 -2.28 7.88 9 Prosphatidylinositol kinase activity (GO.00032742) 0.03077 0.08271 -1.84 7.88 02 Collution Formobal growth factor binding (GO.0003579) 0.03374 0.08271 -1.84 7.84 2 Spindin pole (GO.0003579) 0.063384 0.2061 -1.53 4.40 3 Centricle (GO.00036730) 0.060120 0.001729 0.2081 -1.57 4.41 4 Nucolubia Go.20005730	GO Mole	cular Function 2018				
2 MAP hense prosphase activity (GO.0003549) 0.005885 0.007734 0.07352 -2.48 11.56 3 Transcription correpressor binding (GO.0001222) 0.008670 0.07352 -2.18 10.27 5 Insulin-like growth factor binding (GO.0001221) 0.028071 0.028071 -2.70 9.54 7 Transcription cofactor binding (GO.0003271) 0.00871 0.08271 -2.28 7.83 9 Prosphatidy/inositel kinase binding (GO.0003071) 0.00871 0.08271 -2.28 7.83 10 Bioblast growth factor binding (GO.0003071) 0.00374 0.08271 -1.87 7.87 2 Specific granule membrane (GO.0003579) 0.06394 0.06271 -1.87 5.47 3 Cartricle (GO.000022) 0.06281 0.00122 0.01372 -1.40 4.33 5 Specific granule membrane (GO.0004450) 0.006278 0.2061 -1.47 4.40 4 Musloule (GO.0000221) 0.005710 0.000321 -1.67 4.70 6 Microbule organuize granule (GO.0004250)	1	MAP kinase tyrosine/serine/threonine phosphatase activity (GO:0017017)	0.004791	0.07352	-3.07	16.41
3 Transcription corepresser binding (GO.000122) 0.007774 0.07352 -2.38 11.68 4 Insulin-like growth factor binding (GO.0005520) 0.0088070 0.07352 -2.18 10.27 5 Insulin-like growth factor binding (GO.000194) 0.00871 0.08271 -2.20 9.65 7 Transcription cofector binding (GO.00030971) 0.001540 0.08271 -2.28 6.80 9 Phosphatifylinoshol kinses achinding (GO.0003971) 0.03077 0.08271 -2.28 6.80 9 Phosphatifylinoshol kinses achinding (GO.0003971) 0.00377 0.08271 -2.28 7.83 60 Phosphatifylinoshol kinses achinding (GO.0003774) 0.00377 0.08271 -1.84 7.83 7 Phosphatifylinoshol kinses achinding (GO.0004713) 0.06324 0.2061 -1.87 7.47 8 Pacelife granuile (GO.0002873) 0.06324 0.2061 -1.53 4.40 9 Micolauile (GO.0002814) 0.0001029 0.009725 -3.43 3.61 1 Micolauile gravine (GO.0004281) 0.0001	2	MAP kinase phosphatase activity (GO:0033549)	0.005985	0.07352	-2.64	13.51
4 Insulin-like growth factor binding (GC:0005520) 0.008870 0.07852 -2.18 10.27 5 Insulin-like growth factor binding (GC:000131994) 0.008870 0.07852 -2.0 9.55 7 Tenseription contactor binding (GC:000121) 0.01540 0.08271 -2.29 9.64 8 Receptor tyrosine kinase binding (GC:0001721) 0.01372 0.08271 -2.28 7.93 10 Fibroblast growth factor binding (GC:00052742) 0.03077 0.02671 -1.84 7.88 GCellutromembrane (GC:0005579) 0.05834 0.2061 -1.79 4.95 3 Centrolog (GO:0000622) 0.06238 0.2061 -1.64 4.33 5 Specific granule (GC:0035579) 0.06238 0.2061 -1.64 4.33 5 Specific granule (GC:0042551) 0.06924 0.2061 -1.64 4.33 5 Specific granule (GC:0042551) 0.000128 0.00070 -2.67 2.70 1 MP:0001108_perinatal_tensity_completa_penetrata 0.000324 0.00070 -2.61 3.01 </td <td>3</td> <td>Transcription corepressor binding (GO:0001222)</td> <td>0.007774</td> <td>0.07352</td> <td>-2.38</td> <td>11.56</td>	3	Transcription corepressor binding (GO:0001222)	0.007774	0.07352	-2.38	11.56
5 Insulin-like growth factor i binding (GC: 0031994) 0.008370 0.07352 -2.0 10.02 6 Protein byosine kinase binding (GC: 1900782) 0.015149 0.08271 -2.3 8.80 7 Transcription cofactor binding (GC: 0000271) 0.03077 0.08271 -2.35 8.80 9 Prosphatdy/involto kinase activity (GC: 0052742) 0.03077 0.08271 -2.35 8.80 60 Prosphatdy/involto kinase activity (GC: 0052742) 0.06374 0.02631 -1.74 4.78 7 Transcription cofactor binding (GC: 0003579) 0.06534 0.2061 -1.73 4.40 1 Specific granule membrane (GC: 0035579) 0.06632 0.2061 -1.54 4.33 5 Specific granule (GC: 0005730) 0.06632 0.2061 -1.64 4.33 5 Specific granule (GC: 00042511) 0.006129 0.00767 -2.67 2.70 6 Microtubule organize (GC: 0042511) 0.000129 0.000725 -3.34 30.70 7 MPi0002151_abnorma_neurel, 0.0004251 0.0000271 <t< td=""><td>4</td><td>Insulin-like growth factor binding (GO:0005520)</td><td>0.008965</td><td>0.07352</td><td>-2.18</td><td>10.27</td></t<>	4	Insulin-like growth factor binding (GO:0005520)	0.008965	0.07352	-2.18	10.27
6 Protein tyrosine kinase binding (GC: 1990782) 0.08271 -2.70 9.55 7 Transcription cofactor binding (GC:0000971) 0.01549 0.08271 -2.28 8.80 9 Phosphatidylinoatol kinase activity (GC:00052742) 0.03077 0.08271 -2.28 7.93 10 Fibrobiast growth factor binding (GC:001714) 0.05377 0.08271 -2.28 7.93 10 Specific granule membrane (GC:0005579) 0.06384 0.2061 -1.87 5.47 2 Spindle pole (GO:000092) 0.06032 0.2061 -1.53 4.40 3 Centriola (GO:0005730) 0.06032 0.2061 -1.54 4.33 5 Specific granule (GO:0002821) 0.00027 0.01392 -3.34 30.71 4 Mc:001bub corganity (Go:0044450) 0.000278 0.01392 -3.68 30.40 5 Specific granule (GO:0002821) 0.0002778 0.01392 -3.68 30.40 6 Mc:001128_0.6000781_0 completo_penetrance 0.000278 0.01392 -3.68 30.40 <	5	Insulin-like growth factor I binding (GO:0031994)	0.008370	0.07352	-2.10	10.02
7 Transcription cofactor binding (GO.0001221) 0.01549 0.08271 -2.29 9.54 8 Receptor tyrosine knase binding (GO.00071) 0.02077 0.08271 -2.28 8.90 10 Fbroblast growth factor binding (GO.0005742) 0.03077 0.08271 -2.84 7.83 20 Specific granule membrane (GO.0035573) 0.05834 0.2061 -1.79 4.95 3 Contriol (GO.0000521) 0.06623 0.2061 -1.53 4.40 4 Nucleolus (GO.0005730) 0.06612 0.2061 -1.54 4.33 5 Specific granule (GO.004281) 0.00129 0.00926 0.334 3.01 1 MP.0011089_perinatal_tethality_complexpenetrance 0.000275 0.34 3.01 2 MP.0011089_perinatal_tethality_complexpenetrance 0.000275 0.03927 -2.48 2.01 3 MP.0011089_perinatal_tethality_complexpenetrance 0.000275 0.1392 -2.67 2.06 4 MP.001215_sthormal_neural_tothe_morphology 0.0002767 0.267 2.07 2.01<	6	Protein tyrosine kinase binding (GO: 1990782)	0.02901	0.08271	-2.70	9.55
§Receptor tyrosine kinase binding (GC:0030971)0.023740.08271-2.358.809Prosphatidy/inositol kinase activity (GC:0035742)0.030770.08271-2.287.9310Fibroblast growth factor binding (GC:0017134)0.053740.063740.08271-1.877.832Specific granule membrane (GC:0035579)0.053840.2061-1.875.472Spindle pole (GO:0005814)0.056120.2061-1.534.404Nucleolus (GO:005730)0.060320.2061-1.544.335Specific granule (GC:0042581)0.063240.2103-1.573.746Microtubule organizing center part (GC:0044450)0.07360.000725-3.3430.112MP:0012151_abrormal_neural_tube_memphology0.00010290.000725-3.4830.112MP:001251_abrormal_neural_tube_memphology0.00039420.00707-2.4825.103MP:000295_abrormal_neural_tube_memphology0.00039420.00707-2.4825.114MP:000295_abrormal_neural_cese_longination0.00039420.00707-2.4825.115MP:0003964_abrormal_mutal_exip_printory_quotient0.0001710.02430-2.5611.926MP:0000735_abrormal_mutal_exip_printory_quotient0.00061710.02431-2.4211.927MP:0000735_abrormal_mutal_exip_printory_quotient0.00061710.02430-2.4211.928MP:0000274_abrormal_mutal_exip_printory_quotient0.00006171 <td>7</td> <td>Transcription cofactor binding (GO:0001221)</td> <td>0.01549</td> <td>0.08271</td> <td>-2.29</td> <td>9.54</td>	7	Transcription cofactor binding (GO:0001221)	0.01549	0.08271	-2.29	9.54
9Phosphaticlylinositol kinase activity (GC:0052742)0.030770.08271-2.287.9310Fibrobiast growth factor binding (GC:0017134)0.01320.08271-1.447.88GOGOSpecific granule membrane (GC:00035579)0.053840.02081-1.794.952Spindle pole (GC:0005814)0.060320.2061-1.534.043Centriole (GC:0005730)0.060320.2061-1.644.335Specific granule (GC:00042581)0.092460.2133-1.673.746Microtubule organizing centre part (GC:00404450)0.0001290.009725-3.3430.017MP:0002151_abnormal_neural_tube_morphology0.0001290.000772-3.3430.043MP:001138_decreased_forebrain_size0.00025780.01392-2.7722.946MP:000286_abnormal_neural_cest_cell_migration0.00036420.00707-2.4512.945MP:000738_abnormal_motral_cest_cell_migration0.0005710.02430-2.4712.666MP:0005291_abnormal_motral_development0.0005710.02430-2.4712.667MP:0005291_abnormal_motral_development0.00006170.02430-2.4213.819MP:0005291_abnormal_motral_development0.00006170.02430-2.4213.819MP:0005291_abnormal_motral_development0.00006170.02430-2.4213.811Malar fatering (HP:000072)0.00006170.0243	8	Receptor tyrosine kinase binding (GO:0030971)	0.02374	0.08271	-2.35	8.80
10Ploroblast growth factor binding (GC:0017134)0.013720.08271-1.847.88Colspan="6">Colspan="6">Colspan="6"C	9	Phosphatidylinositol kinase activity (GO:0052742)	0.03077	0.08271	-2.28	7.93
Specific granule membrane (0C:0035579) 0.05394 0.02061 -1.67 5.47 2 Spindle pole (GC:0000922) 0.06023 0.2061 -1.53 4.40 4 Nucleolus (GC:0005814) 0.06012 0.2061 -1.53 4.40 5 Specific granule (GC:0002570) 0.000120 0.00012 0.2061 -1.64 4.33 5 Specific granule (GC:0042581) 0.00120 0.00120 0.00120 -1.40 0.364 6 Microtubule organizing center part (GC:0044450) 0.000120 0.000725 -3.34 9.01 7 MP:0011989_perinatal_ethality_complete_penetrance 0.0002578 0.01392 -3.68 30.40 3 MP:001198_decreased_resprain_size 0.0000342 0.00707 -2.48 25.19 6 MP:0001378_increased_respraintog_development 0.0002570 0.01392 -2.77 2.94 7 MP:000138_abnormal_muscle_development 0.000511 0.00433 -2.65 18.19 7 MP:000251_abnormal_muscle_development 0.000517 0.02463 -2.62 18.6 8 MP:0002521_abnormal_muscle	10	Fibroblast growth factor binding (GO:0017134)	0.01372	0.08271	-1.84	7.88
1Specific granule membrane (GO:0035579)0.053840.2061-1.874.962Spindle pole (GO:000522)0.062930.2061-1.534.403Ontrolic (GO:0005730)0.066120.2061-1.544.335Specific granule (GO:0042581)0.092460.2133-1.573.746Mcrotubile organizing center part (GO:004450)0.0010290.009725-3.349.0717MP:002151_abnormal_neural_tube_morphology0.00010290.009725-3.349.0712MP:0011089_perinatal_lethality_complete_penetrance0.000039420.007070-2.6727.063MP:0012138_dcereased_forebrain_size0.000039420.007070-2.6722.016MP:0002561_abnormal_neural_cubepment0.000025420.01392-2.7722.946MP:0003864_abnormal_muscl_development0.00005170.02463-2.5619.297MP:000733_abnormal_muscl_development0.00065170.02463-2.6618.7610MP:0002521_abnormal_muscl_development0.00065170.02463-2.4218.06Humerity total abis_patterning0.00065170.02463-2.422.1610MP:0005261_dcoreased_anglogenesis0.00005170.02463-2.422.6011Malar fattering (HP:000727)2.943.000034500.0002569-2.022.4212Malar fattering (HP:0000452)0.000045180.000753-2.022.4213Malar fattering (HP:00	GO Cellu	ar Component 2018				
2Spindle pole (GO:0000922)0.062930.2061-1.794.953Centriole (GO:0005730)0.060320.2061-1.544.404Nucleolus (GO:0005730)0.060320.2061-1.544.335Specific granule (GO:0042591)0.073610.2061-1.403.846Microtubule organizing centre part (GO:0044450)0.073610.2061-1.403.84MICO101080_perinatal_lethalty_complete_penetrance0.0001290.009725-3.3430.712MP:001151_ahnormal_neural_tope_penetrance0.00003420.00707-2.6727.064MP:001138_iccreased_combrain_size0.000039420.00707-2.4825.105MP:001378_increased_respiratory_quotient0.00025420.01392-2.7722.946MP:000378_increased_angiogenesis0.00051710.02463-2.5619.299MP:0005602_decreased_angiogenesis0.00051710.02463-2.6618.7510MP:0002111_ahnormal_midbrain_prophogy0.000051710.002659-2.423.0321Midface retrusion (HP:0011800)0.000034500.00065170.002635-2.422.5132Midface retrusion (HP:0011800)0.000034500.00034500.001761-2.262.2634Camptodetyly of finger (HP:010490)0.000034500.0005610.001761-2.422.5134Midface retrusion (HP:0000600)0.000034500.001563-2.022.612.61<	1	Specific granule membrane (GO:0035579)	0.05384	0.2061	-1.87	5.47
3Centrole (GO:0005814)0.056120.2061-1.534.404Nucleolus (GO:0005730)0.060320.2061-1.544.335Specific granule (GO:0042581)0.092460.2133-1.573.746Microtubue organizing center part (GO:004450)0.0010290.007261-1.403.64MP:0002151_abnormal_neural_tube_morphology0.00010290.009725-3.3430.712MP:0011089_peninatal_iethality_complete_penetrance0.00025780.01392-3.6830.403MP:001213_decreased_forebrain_size0.000039420.007070-2.6722.014MP:000250_abnormal_neural_cube_ingration0.00025420.01392-2.7722.946MP:000384_abnormal_mucral_cele_ingration0.00025420.01304-2.4521.197MP:000573_abnormal_mucral_cele_ingration0.0005110.02463-2.6519.268MP:000521_abnormal_optin-ceuda_axis_patterning0.0005110.02463-2.4718.089MP:0005602_decreased_angiogenesis0.00006170.0046370.01761-2.2624.2610MP:000521_abnormal_tell_morphology0.000045670.007645-2.4230.882Midface retrusion (HP:0018000.000045670.007645-2.6224.263Midface retrusion (HP:0018000.000045670.001553-2.1224.464Abal fattering (HP:000452)0.000045670.001563-2.1224.164Mair f	2	Spindle pole (GO:0000922)	0.06293	0.2061	-1.79	4.95
4Nucleolus (G0:0005730)0.060320.2061-1.544.335Specific granule (G0:0042581)0.092460.2133-1.573.746Microtube organizing center part (G0:004450)0.073610.2061-1.543.64MB:002151_abnormal_neural_tube_morphology0.00012990.009725-3.3430.712MP:0011089_perinatal_iethality_complete_penetrance0.00039420.00707-2.6727.064MP:001273_decreased_forebrain_size0.00039420.00707-2.6722.165MP:000378_increased_respiratory_quotient0.00025420.01392-2.7722.946MP:000373_abnormal_midbrain_development0.00005110.00707-2.1120.667MP:000522_abnormal_costra-cauda_axis_patterning0.0005110.02463-2.4519.299MP:000522_abnormal_costra-cauda_axis_patterning0.0005110.02463-2.4230.869MP:000522_abnormal_costra-cauda_axis_patterning0.0006170.02463-2.4230.869MP:0002711_abnormal_tai_morphology0.00004510.00025420.00176-2.4220.8610Macratutening (HP:000272)2.010.00004510.00025420.01761-2.4220.862Midrac retrusion (HP:001480)0.00004510.00024500.001763-2.1220.423Midrac retrusion (HP:001480)0.00004510.00034500.01553-2.1221.414Macratutening (HP:000452)0.0000	3	Centriole (GO:0005814)	0.05612	0.2061	-1.53	4.40
5 Specific granule (GO:0042581) 0.09246 0.2133 -1.57 3.74 6 Microtubule organizing center part (GO:0044450) 0.07361 0.2061 -1.40 3.64 MGI Memory 20151 second cond cond cond cond cond cond cond	4	Nucleolus (GO:0005730)	0.06032	0.2061	-1.54	4.33
6Microtubule organizing center part (GO:004450)0.073610.2061-1.403.64Henotype 20171MP:002151_abnormal_neural_tube_morphology0.0010290.009725-3.3430.712MP:001188_decreased_forebrain_size0.00025780.01392-2.6830.004MP:002380_abnormal_neural_crest_cell_migration0.00039420.007070-2.4825.105MP:001378_increased_respiratory_quotient0.00025420.01392-2.7722.946MP:0003864_abnormal_micbrain_development0.0005110.00243-2.4521.197MP:000521_abnormal_nuscle_development0.0005110.02443-2.5618.7510MP:000521_abnormal_notsle_development0.0005170.02463-2.4230.8810MP:000521_abnormal_rostle_development0.0005170.02463-2.4230.8810MP:000521_abnormal_rostle_development0.0005170.02463-2.4230.8811Malfattening (HP:0000272)0.0005170.002450-2.4230.882Midrace retrusion (HP:001480)0.00006180.000259-2.4224.263Midrace retrusion (HP:0000586)0.00004500.00153-2.4224.264Choanal stensis (HP:0000586)0.00004500.000553-2.0224.264Mallow orbits (HP:0000586)0.00004500.00153-2.622.125Mallow orbits (HP:0000586)0.00001610.0002561-0.0153-2.62	5	Specific granule (GO:0042581)	0.09246	0.2133	-1.57	3.74
Hendyper 20171MP:0002151_abnormal_neural_tube_morphology0.00010290.009725-3.3430.712MP:0011089_perinatal_lethality_complete_penetrance0.00025780.01392-3.6830.403MP:001238_decreased_forebrain_size0.000039420.007070-2.6727.084MP:000386_abnormal_neural_crest_cell_migration0.00025420.01392-2.7722.945MP:000386_abnormal_midbrain_development0.00025420.01304-2.4521.197MP:0005221_abnormal_rostral-caudal_axis_patterning0.00051710.02443-2.5519.299MP:0005602_decreased_angiogenesis0.000051710.02463-2.6618.7510MP:0000602_decreased_angiogenesis0.000034500.00085170.20463-2.6224.2611Midrace retrusion (HP:0000272)0.000034500.00085170.000859-2.4220.2222Midrace retrusion (HP:011800)0.000034500.0008563-2.0224.2634Midrace retrusion (HP:0100490)0.000034500.001563-2.1522.1445Shallow orbits (HP:0000586)0.000034500.001563-2.0224.2654Verteral obstruction (HP:0000586)0.000034500.001563-2.0224.2654Shallow orbits (HP:0000586)0.000034500.001563-2.1522.1455Shalow orbits (HP:0000586)0.000034500.001563-2.022.16764Uretral obstruction (HP:000071) </td <td>6</td> <td>Microtubule organizing center part (GO:0044450)</td> <td>0.07361</td> <td>0.2061</td> <td>-1.40</td> <td>3.64</td>	6	Microtubule organizing center part (GO:0044450)	0.07361	0.2061	-1.40	3.64
1 MP:0002151_abnormal_neural_tube_morphology 0.0001029 0.000725 -3.34 30.71 2 MP:0011089_perinatal_ethality_complete_penetrance 0.00003942 0.007070 -2.67 27.06 3 MP:0012138_decreased_forebrain_size 0.00003942 0.007070 -2.67 27.06 4 MP:000256_abnormal_neural_crest_cell_migration 0.0002542 0.01392 -2.77 22.94 5 MP:0003864_abnormal_meural_development 0.0001725 0.01304 -2.45 21.19 7 MP:0005221_abnormal_ostral-caudal_axis_patterning 0.000511 0.02443 -2.56 19.29 8 MP:0005602_decreased_angiogenesis 0.000617 0.02463 -2.47 18.08 10 MP:0002111_abnormal_tal_morphology 0.000617 0.02463 -2.42 30.38 2 MP:0002111_abnormal_tal_morphology 0.000617 0.0008257 -2.42 30.38 2 MP:0002111_abnormal_tal_morphology 0.0000618 0.0008257 -2.42 30.38 2 Midface retrusion (HP:001800 0.00004567 0.01761 -2.42 2.28 2 Salow or	MGI Mam	malian Phenotype 2017				
2 MP:0011089_perinatal_ethality_complete_penetrance 0.0002578 0.01392 -3.68 30.40 3 MP:0012138_decreased_forebrain_size 0.00003942 0.007070 -2.67 27.06 4 MP:0010378_increased_respiratory_quotient 0.0002542 0.01392 -2.77 22.94 6 MP:000386_abnormal_muscle_development 0.0002511 0.007070 -2.11 20.66 7 MP:000502_decreased_angiogenesis 0.000511 0.02443 -2.55 19.29 9 MP:000560_decreased_angiogenesis 0.0006517 0.2463 -2.47 18.76 10 MP:000560_decreased_angiogenesis 0.0006517 0.02463 -2.47 18.76 10 MP:000502_decreased_angiogenesis 0.0006517 0.02463 -2.42 30.38 21 Midrace retrusion (HP:0000272) 0.000617 0.000617 0.2463 -2.02 2.42 32 Camptodactyly of finger (HP:010490) 0.00004567 0.001761 -2.26 2.28 34 Chanal stenosis (HP:0000452) 0.00004567 0.001	1	MP:0002151_abnormal_neural_tube_morphology	0.0001029	0.009725	-3.34	30.71
3MP:0012138_decreased_forebrain_size0.000039420.007070-2.6727.064MP:0002950_abnormal_neural_crest_cel_migration0.000039420.007070-2.4825.105MP:0010378_increased_respiratory_quotient0.00025420.01392-2.7722.946MP:000733_abnormal_midbrain_development0.00005110.007070-2.1120.667MP:000521_abnormal_rostral-caudal_axis_patterning0.0005110.02433-2.5619.299MP:0005602_decreased_angiogenesis0.00065170.02463-2.6718.7510MP:0002111_abnormal_tail_morphology0.00065170.02463-2.6218.7511Malar fatterning (HP:000272)0.000034550.0008519-2.4230.382Midface retrusion (HP:0010429)0.000004560.000034500.000859-2.0224.263Camptodactyly of finger (HP:0100490)0.000004560.000034500.00153-2.1621.164Shallow orbits (HP:0000586)0.000021710.00153-2.0221.6221.625Midrace retrusion (HP:000600)0.000034500.00153-2.0221.6221.626Ureteral bestruction (HP:0000586)0.00007140.001533-2.0221.6221.627Short nose (HP:0001451)0.0007140.00079890.002546-2.2621.6221.627Short nose (HP:000071)0.00007110.00079890.002546-2.0221.6221.628Uret	2	MP:0011089_perinatal_lethality,_complete_penetrance	0.0002578	0.01392	-3.68	30.40
4MP:0002950_abnormal_neural_crest_cell_migration0.000039420.007070-2.4825.105MP:0010378_increased_respiratory_quotient0.00025420.01392-2.7722.946MP:0003864_abnormal_midbrain_development0.00017250.01304-2.4521.197MP:000733_abnormal_muscle_development0.00056110.007070-2.1120.668MP:0005602_decreased_angiogenesis0.0006170.02433-2.5618.7510MP:0002111_abnormal_tail_morphology0.0006170.02463-2.4718.08Human Human Human Latil_morphology0.00006170.0008570.008259-2.4230.382Midface retrusion (HP:0000272)0.000004150.000034550.0008259-2.4224.263Camptodactyly of finger (HP:010490)0.00004160.000034500.001761-2.2622.604Choanal stenosis (HP:0000586)0.000021710.001553-2.0221.675Shallow orbits (HP:0000586)0.000021710.001553-2.0221.676Ureteral obstruction (HP:0000600)0.000034500.001553-2.0221.677Short nose (HP:0003196)0.00007110.00029100.001553-2.0221.678Ureteral obstruction (HP:0000071)0.00007110.000029100.001553-2.0221.679Heterogeneous (HP:0001425)0.00007110.000029100.001553-2.0221.6710Depresed nasal bridge (HP:0005280) <td>3</td> <td>MP:0012138_decreased_forebrain_size</td> <td>0.00003942</td> <td>0.007070</td> <td>-2.67</td> <td>27.06</td>	3	MP:0012138_decreased_forebrain_size	0.00003942	0.007070	-2.67	27.06
5MP:0010378_increased_respiratory_quotient0.00025420.01392-2.7722.946MP:0003864_abnormal_midbrain_development0.00017250.01304-2.4521.197MP:000733_abnormal_muscle_development0.00056110.007070-2.1120.668MP:0005602_decreased_angiogenesis0.00051710.02433-2.5519.299MP:0002111_abnormal_tail_morphology0.00065170.02463-2.4718.0810MP:0002111_abnormal_tail_morphology0.00065170.008259-2.4230.3821Malar flattening (HP:0000272)0.000034500.00002702.0224.2630Camptodactyly of finger (HP:011800)0.00004180.00021710.00153-2.0224.2631Camptodactyly of finger (HP:0100490)0.000021710.00153-2.1522.144Choanal stensis (HP:0000586)0.000021710.00153-2.0221.675Shallow orbits (HP:0000586)0.000021710.00153-2.0221.637Short nose (HP:0003196)0.00007180.00073800.00153-2.0221.328Ureteral stensis (HP:000071)0.00007180.00029100.00153-2.0120.939Hetorgeneous (HP:001425)0.0000710.00029110.00153-2.0120.9310Depressed naaal bridge (HP:005280)0.00029110.0002460.00154-2.1420.06	4	MP:0002950_abnormal_neural_crest_cell_migration	0.00003942	0.007070	-2.48	25.10
64MP:003864_abnormal_midbrain_development0.00017250.01304-2.4521.197MP:000733_abnormal_muscle_development0.00056110.007070-2.1120.668MP:000521_abnormal_rostral-caudal_axis_patterning0.00051710.02433-2.5519.299MP:000502_decreased_angiogenesis0.00061700.02463-2.4718.0810MP:0002111_abnormal_tail_morphology0.00061700.008259-2.4230.382Malar flattening (HP:0000272)0.000034500.0008259-2.4230.382Midface retrusion (HP:0011800)0.000045670.0008259-2.0224.263Camptodactyl of finger (HP:0100490)0.000045670.001761-2.2622.604Choanal stenosis (HP:0000586)0.000021710.001533-2.0221.165Shallow orbits (HP:0000586)0.000021710.001533-2.0221.616Ureteral obstruction (HP:0003196)0.00007190.000029100.001533-2.0221.327Short nose (HP:0003196)0.0000710.000029100.001533-2.0120.939Heterogeneous (HP:001425)0.0000710.000084870.002546-2.1420.0610Depresed nasab bridge (HP:0005280)0.0002810.0002810.007161-2.3719.00	5	MP:0010378_increased_respiratory_quotient	0.0002542	0.01392	-2.77	22.94
7MP:000733_abnormal_muscle_development0.000056110.00770-2.1120.688MP:0005221_abnormal_ostral-caudal_axis_patterning0.00051710.02433-2.5519.299MP:0005602_decreased_angiogenesis0.00065170.02463-2.4718.0810MP:0002111_abnormal_tai_morphology0.00065170.02463-2.4718.08Human Pi-type Ontology1Malar flattening (HP:000272)0.000034550.0008259-2.4230.382Midface retrusion (HP:011800)0.0000041810.0008250-2.0224.263Camptodactyly of finger (HP:010490)0.000045670.001761-2.2622.604Choanal stenosis (HP:000586)0.000034500.001553-2.1522.165Shallow orbits (HP:0005080)0.000034500.001553-2.0221.626Ureteral obstruction (HP:000600)0.000034500.001553-2.0221.627Short nose (HP:0003196)0.00007110.00029100.001553-2.0221.628Ureteral stenosis (HP:000071)0.000084770.00028470.002546-2.1420.069Hetrogeneous (HP:0001425)0.00008470.00028470.002546-2.1420.0610Depressed nasal bridge (HP:0005280)0.00029810.0007810.00151-2.3719.20	6	MP:0003864_abnormal_midbrain_development	0.0001725	0.01304	-2.45	21.19
8MP:005221_abnormal_rostral-caudal_axis_patterning0.00051710.02433-2.5519.299MP:005602_decreased_angiogenesis0.00065170.02463-2.6618.7510MP:0002111_abnormal_tail_morphology0.00065170.02463-2.4718.08Human H=************************************	7	MP:0000733_abnormal_muscle_development	0.00005611	0.007070	-2.11	20.66
9MP:0005602_decreased_angiogenesis0.00065170.02463-2.5618.7510MP:0002111_abnormal_tai_morphology0.00065170.02463-2.4718.08Human P-type Ontology1Malar flattening (HP:000272)0.000034550.0008259-2.4230.382Midface retrusion (HP:01180)0.00004180.0008250-2.0224.263Camptodactyly of finger (HP:0100490)0.000045670.001761-2.2622.604Choanal stenosis (HP:000452)0.000034500.001553-2.1522.145Shallow orbits (HP:000586)0.000021710.01553-2.0221.626Ureteral obstruction (HP:000600)0.000079800.001553-2.0221.327Short nose (HP:0003196)0.00007910.00029100.001553-2.0221.328Ureteral stenosis (HP:0001425)0.00007910.001553-2.012.039Hetrogeneous (HP:001425)0.00007910.002546-2.012.0310Depresed nasal bridge (HP:005280)0.0002910.00153-2.142.04	8	MP:0005221_abnormal_rostral-caudal_axis_patterning	0.0005171	0.02443	-2.55	19.29
10MP:002111_abnormal_tail_morphology0.00065170.02463-2.4718.08Human P-type Ontology1Malar flattening (MP:000272)0.000034550.0008259-2.4230.382Midface retrusion (MP:011800)0.000061180.0008259-2.0224.263Camptodactyly of finger (MP:0100490)0.000045670.001761-2.2622.604Choanal stenosis (MP:000452)0.000034500.001553-2.1522.145Shallow orbits (MP:000586)0.000021710.01553-2.0221.626Ureteral obstruction (MP:0006000)0.000079800.002546-2.2621.327Short nose (MP:0003196)0.00007910.00029910.001553-2.012.0939Hetorgeneous (MP:0001425)0.0000710.00028470.002546-2.142.09310Depresed nasal bridge (MP:0005280)0.0002810.0007161-2.3719.20	9	MP:0005602_decreased_angiogenesis	0.0006517	0.02463	-2.56	18.75
Human Pheroper Detailong1Malar flattening (HP:000272)0.000034550.0008259-2.4230.382Midface retrusion (HP:01180)0.000061180.0008259-2.0224.263Camptodactyly of finger (HP:0100490)0.000045670.001761-2.2622.604Choanal stenosis (HP:000452)0.000034500.001553-2.1522.145Shallow orbits (HP:000586)0.000021710.001553-2.0221.676Ureteral obstruction (HP:000600)0.000034500.001553-2.0821.327Short nose (HP:0003196)0.000079800.002546-2.2621.328Ureteral stenosis (HP:00071)0.000084770.002546-2.1420.089Heterogeneous (HP:001425)0.00029810.007161-2.3719.2010Depresed nasal bridge (HP:005280)0.00029810.007161-2.3719.20	10	MP:0002111_abnormal_tail_morphology	0.0006517	0.02463	-2.47	18.08
1 Malar flattening (HP:0000272) 0.00003455 0.0008259 -2.42 30.38 2 Midface retrusion (HP:011800) 0.00006118 0.0008259 -2.02 24.26 3 Camptodactyly of finger (HP:0100490) 0.00004567 0.001761 -2.26 22.60 4 Choanal stenosis (HP:0000452) 0.00003450 0.001553 -2.15 22.14 5 Shallow orbits (HP:000586) 0.00002171 0.001553 -2.02 21.67 6 Ureteral obstruction (HP:0006000) 0.00003450 0.001553 -2.08 21.32 7 Short nose (HP:0003196) 0.00007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:000071) 0.00007989 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.0000991 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	Human P	henotype Ontology				
2 Midface retrusion (HP:0011800) 0.00006118 0.0008259 -2.02 24.26 3 Camptodactyly of finger (HP:0100490) 0.00004567 0.001761 -2.26 22.60 4 Choanal stenosis (HP:0000452) 0.00003450 0.001553 -2.15 22.14 5 Shallow orbits (HP:000586) 0.00002171 0.001553 -2.02 21.67 6 Ureteral obstruction (HP:0006000) 0.00003450 0.001553 -2.08 21.32 7 Short nose (HP:0003196) 0.00007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:000071) 0.00002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.00002847 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	1	Malar flattening (HP:0000272)	0.000003455	0.0008259	-2.42	30.38
3 Camptodactyly of finger (HP:0100490) 0.0004567 0.001761 -2.26 22.60 4 Choanal stenosis (HP:000452) 0.0003450 0.001553 -2.15 22.14 5 Shallow orbits (HP:000586) 0.00002171 0.001553 -2.02 21.67 6 Ureteral obstruction (HP:0006000) 0.00003450 0.001553 -2.08 21.39 7 Short nose (HP:0003196) 0.00007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:000071) 0.00002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.00008487 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	2	Midface retrusion (HP:0011800)	0.000006118	0.0008259	-2.02	24.26
4 Choanal stenosis (HP:000452) 0.0003450 0.001553 -2.15 22.14 5 Shallow orbits (HP:000586) 0.0002171 0.01553 -2.02 21.67 6 Ureteral obstruction (HP:0006000) 0.0003450 0.001553 -2.02 21.39 7 Short nose (HP:0003196) 0.00007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:000071) 0.00002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.0002981 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	3	Camptodactyly of finger (HP:0100490)	0.00004567	0.001761	-2.26	22.60
5 Shallow orbits (HP:000586) 0.0002171 0.001553 -2.02 21.67 6 Ureteral obstruction (HP:0006000) 0.0003450 0.001553 -2.08 21.39 7 Short nose (HP:0003196) 0.00007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:000071) 0.0002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.0002847 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	4	Choanal stenosis (HP:0000452)	0.00003450	0.001553	-2.15	22.14
6 Ureteral obstruction (HP:0006000) 0.0003450 0.001553 -2.08 21.39 7 Short nose (HP:0003196) 0.0007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:000071) 0.00002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.0008487 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	5	Shallow orbits (HP:0000586)	0.00002171	0.001553	-2.02	21.67
7 Short nose (HP:0003196) 0.0007989 0.002546 -2.26 21.32 8 Ureteral stenosis (HP:0000071) 0.0002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.0008487 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	6	Ureteral obstruction (HP:0006000)	0.00003450	0.001553	-2.08	21.39
8 Ureteral stenosis (HP:000071) 0.0002991 0.001553 -2.01 20.93 9 Heterogeneous (HP:0001425) 0.0008487 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	7	Short nose (HP:0003196)	0.00007989	0.002546	-2.26	21.32
9 Heterogeneous (HP:0001425) 0.0008487 0.002546 -2.14 20.06 10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	8	Ureteral stenosis (HP:0000071)	0.00002991	0.001553	-2.01	20.93
10 Depressed nasal bridge (HP:0005280) 0.0002981 0.007161 -2.37 19.20	9	Heterogeneous (HP:0001425)	0.00008487	0.002546	-2.14	20.06
	10	Depressed nasal bridge (HP:0005280)	0.0002981	0.007161	-2.37	19.20

(Continued)

TABLE 1 | Continued

				A 11 1		
			Adjusted	Combined		
Index	Name	P-value	p-value	Z-score	score	
Jensen TISSUES						
1	Ectoderm	0.00006469	0.005546	-4.15	39.98	
2	Cranium	0.00007203	0.005546	-4.00	38.17	
3	Retina	0.008991	0.09231	-7.36	34.68	
4	Adult	0.01554	0.09772	-6.50	27.05	
5	Neural crest	0.002981	0.06593	-4.14	24.10	
6	Somite	0.0005354	0.02749	-3.08	23.19	
7	Bud	0.001676	0.05163	-3.59	22.95	
8	Mesenchyme	0.01050	0.09772	-5.01	22.84	
9	Myoblast	0.001550	0.05163	-3.53	22.83	
10	Immune system	0.02200	0.1019	-5.91	22.56	

Only the top-10 functions have been included (whenever available). The p-value was computed using Fisher's exact test. The adjusted p-value was computed using the Benjamini-Hochberg method for correction for multiple hypotheses testing. The z-score was computed using a modification to Fisher's exact test and assess the deviation from the expected rank. Finally, the combined score is a combination of the p-value and z-score calculated by multiplying the two scores (combined score = ln(p-value) * z-score). This combined score provides a compromise between both methods and it is claimed to report the best rankings when compared with the other scoring schemes. See http://amp.pharm.mssm.edu/Enrichr/help#background&q=5 for details.

Schmitt et al., 2001; Thompson et al., 2005; Jackowski et al., 2009). Finally, variants of *NFXL1*, which is predicted to encode a transcription factor, confer a risk for SLI (Villanueva et al., 2015). The gene is highly expressed in the cerebellum (Nudel, 2016).

Regarding the candidates for language evolution that we have found downregulated in the blood of subjects with WS, DUSP1 is involved in vocal learning in songbirds (Horita et al., 2010, 2012). PVALB encodes a calcium-binding protein that is structurally and functionally similar to calmodulin and that is involved in hippocampal plasticity, learning and memory (Donato et al., 2013). Interestingly enough, the inactivation of Pvalbexpressing interneurons in the auditory cortex alters response to sound, strengthening forward suppression and altering its frequency dependence (Phillips et al., 2017). Inhibition of PVALB-expressing GABAergic interneurons results in complex behavioral changes related to the behavioral phenotype of people with SZ (Brown et al., 2015). Importantly, some of the key changes that contributed to the emergence of our language-readiness involved GABAergic signaling (discussed in detail in Boeckx and Benítez-Burraco, 2014b), which are vital for oscillatory processes underlying language processing (Bae et al., 2010; see Murphy and Benítez-Burraco, 2018 for details). Reduction in PVALB expression in interneurons has also been found in mouse models of ASD (Filice et al., 2016), specifically, in the Cntnap2-/- model (Lauber et al., 2018). CNTNAP2 is a direct target of FOXP2, the renowned "language gene" (Vernes et al., 2008; Adam et al., 2017), and regulates language development in non-pathological populations too (Whitehouse et al., 2011; Whalley et al., 2011, Kos et al., 2012). Also mice lacking PLAUR have significantly fewer neocortical parvalbumin-containing GABAergic interneurons, with this reduction correlating with impaired social interactions (Bruneau and Szepetowski, 2011). PLAUR is a target of FOXP2 too (Roll et al., 2010), but also an effector of SRPX2, another of FOXP2's targets (Royer-Zemmour et al., 2008) and a candidate for speech dyspraxia (Roll et al., 2006). Concerning PAX3, this gene is expressed in the neural

crest and is a candidate for Waardenburg syndrome, a clinical condition entailing sensorineural hearing loss and developmental delay (Tassabehji et al., 1992; Chen et al., 2010). Finally, *ITGB4* encodes the integrin beta 4 subunit, a receptor for the laminins, including FLNA (Travis et al., 2004), an actin-binding protein needed for cytoskeleton remodeling and neuronal migration (Fox et al., 1998) FLNA binds *CMIP* (Fox et al., 1998), a candidate for SLI (Newbury et al., 2009). Interestingly enough, ITGB4 is one of the proteins bearing fixed changes in humans compared to extinct hominins (Pääbo, 2014; **Supplementary Table S1**).

Lastly, among the genes found to be upregulated in the blood on WS subjects, we found the SLI candidate SETBP1, as well as FGFR1 and SIX3. SETBP1 is also a candidate for Schinzel-Giedion syndrome, a clinical condition entailing occasional epilepsy and severe developmental delay (Ko et al., 2013; Miyake et al., 2015). Mutations on this gene have been associated as well to behavioral and social deficits (Coe et al., 2014). The Integrative Nuclear FGFR1 Signaling (INFS) has been hypothesized to be one of the neurodevelopmental pathways on which multiple SZ candidates converge, regulating numerous neurotransmitter systems and neural circuits (Stachowiak et al., 2013). Finally, SIX3 contributes to regulate the relative size of the telencephalon versus the thalamus (Lavado et al., 2008; Sylvester et al., 2010). Interestingly, Six3 regulates Shh (Jeong et al., 2008), one robust candidate for microcephaly that has been positively selected in the human lineage (Dorus et al., 2004), but it also interacts with several genes relevant for our language-ready brain (Benítez-Burraco and Boeckx, 2015).

Functional Characterization of the Set of Dysregulated Genes

The results of our functional enrichment analyses (**Table 1**) show that the language-related genes that are dysregulated in the blood of people with WS mainly contribute to the cytoskeleton activity, being significantly involved in cell proliferation and migration,

including neuroblast proliferation. Regarding their molecular function, they typically participate in protein modification, particularly via (tyrosine) kinase phosphatase and (tyrosine) kinase binding activities, but also in gene regulation, via transcription cofactor binding. Interestingly, these genes are significantly associated to aberrant processes impacting on brain development, like abnormal neural tube morphology and neural crest cell migration, as well as decreased forebrain size and abnormal midbrain development. Likewise, they are associated to clinical symptoms mostly impacting on craniofacial morphology, like malar flattening, midface retrusion, shallow orbits, or depressed nasal bridge. Finally, these genes are predicted to be preferentially expressed in the ectoderm, the cranium, the retina, and the neural crest. According to the Human Brain Transcriptome Database¹all these genes are expressed in the brain, particularly in the thalamus and the cerebellum (Supplementary Table S2). The thalamus functions as a sort of relay center to connect many brain areas involved in language processing (Wahl et al., 2008; Murdoch, 2010; David et al., 2011) and changes in the thalamus have been claimed to contribute to the evolutionary emergence of our language-ready brain (see Boeckx and Benítez-Burraco, 2014b for details). Similarly, the cerebellum plays a key role in language processing and is impaired in language-related pathologies (Vias and Dick, 2017; Mariën and Borgatti, 2018). People with WS exhibit cerebellar volume alterations that are seemingly associated with their cognitive, affective and motor distinctive features (Osório et al., 2014). In the same vein, the thalamus exhibits structural and functional differences with the neurotypical population, including disproportionately reduced volumes and decreased gray matter (Chiang et al., 2007; Campbell et al., 2009), as well as enhanced thalamic activity (Mobbs et al., 2007; Bódizs et al., 2012).

CONCLUSION

To conclude, it is true that deciphering the exact molecular causes of language dysfunction in WS is still pending, particularly,

¹ http://hbatlas.org

REFERENCES

- Adam, I., Mendoza, E., Kobalz, U., Wohlgemuth, S., and Scharff, C. (2017). CNTNAP2 is a direct FoxP2 target in vitro and in vivo in zebra finches: complex regulation by age and activity. *Genes Brain Behav.* 16, 635–642. doi: 10.1111/ gbb.12390
- Alkelai, A., Lupoli, S., Greenbaum, L., Kohn, Y., Kanyas-Sarner, K., Ben-Asher, E., et al. (2012). DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. *Int. J. Neuropsychopharmacol.* 15, 459–469. doi: 10. 1017/S1461145711000903
- Bae, M. H., Bissonette, G. B., Mars, W. M., Michalopoulos, G. K., Achim, C. L., Depireux, D. A., et al. (2010). Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. *Exp. Neurol.* 221, 129–135. doi: 10.1016/j.expneurol.2009.10.011
- Bellugi, U., Lichtenberger, L., Mills, D., Galaburda, A., and Korenberg, J. R. (1999). Bridging cognition, the brain and molecular genetics: evidence from Williams syndrome. *Trends Neurosci.* 5, 197–207. doi: 10.1016/S0166-2236(99)01397-1

because at present none of the genes hemideleted in this condition has been demonstrated to play a central role in language processing. Nonetheless, in this paper we have shown that the genes that are dysregulated in subjects with WS are significantly enriched in core candidates for language disorders and language evolution. These genes emerge as robust candidates for language dysfunction in WS. Future research should try to delve into the expression patterns of these genes in the brain of people with WS, as well as into their role in neurotypical brain development. Likewise, altering these genes in animal models of WS should help gaining a better understanding of their biological role and ultimately, of their contribution to language dysfunction in WS.

DATA AVAILABILITY

Publicly available datasets were analyzed in this study. This data can be found here: https://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE89594.

AUTHOR CONTRIBUTIONS

AB-B conceived and wrote the manuscript. RK conducted the expression studies and analyzed the data. Both authors contributed to manuscript revision, and read and approved the submitted version.

FUNDING

This research was funded by the Spanish Ministry of Economy and Competitiveness [Grant FFI2016-78034-C2-2-P (AEI/FEDER, UE) to AB-B].

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnins. 2019.00258/full#supplementary-material

- Benítez-Burraco, A. (2013). "Genetics of language: roots of specific language deficits," in *The Cambridge Handbook of Biolinguistics*, eds C. Boeckx and K. K. Grohmann (Cambridge: Cambridge University Press), 375–412.
- Benítez-Burraco, A., and Boeckx, C. (2015). Possible functional links among brainand skull-related genes selected in modern humans. *Front. Psychol.* 6:794. doi: 10.3389/fpsyg.2015.00794
- Benítez-Burraco, A., and Murphy, E. (2016). The oscillopathic nature of language deficits in autism: from genes to language evolution. *Front. Hum. Neurosci.* 10:120. doi: 10.3389/fnhum.2016.00120
- Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate a practical and powerful approach to multiple testing. *J. R. Stat. Soc. Series B* 57, 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x
- Bódizs, R., Gombos, F., and Kovács, I. (2012). Sleep EEG fingerprints reveal accelerated thalamocortical oscillatory dynamics in Williams syndrome. *Res. Dev. Disabil.* 33, 153–164. doi: 10.1016/j.ridd.2011.09.004
- Boeckx, C., and Benítez-Burraco, A. (2014a). Globularity and languagereadiness: generating new predictions by expanding the set of

genes of interest. Front. Psychol. 5:1324. doi: 10.3389/fpsyg.2014. 01324

- Boeckx, C., and Benítez-Burraco, A. (2014b). The shape of the human languageready brain. Front. Psychol. 5:282. doi: 10.3389/fpsyg.2014.00282
- Boyle, E. A., Li, Y. I., and Pritchard, J. K. (2017). An expanded view of complex traits: from polygenic to omnigenic. *Cell* 169, 1177–1186. doi: 10.1016/j.cell. 2017.05.038
- Brock, J. (2007). Language abilities in Williams syndrome: a critical review. Dev. Psychopathol. 19, 97–127. doi: 10.1017/S095457940707006X
- Brown, J. A., Ramikie, T. S., Schmidt, M. J., Báldi, R., Garbett, K., Everheart, M. G., et al. (2015). Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes. *Mol. Psychiatry* 20, 1499–1507. doi: 10.1038/ mp.2014.192
- Brown, N. J., Marjanović, M., Lüders, J., Stracker, T. H., and Costanzo, V. (2013). Cep63 and cep152 cooperate to ensure centriole duplication. *PLoS One* 8:e69986. doi: 10.1371/journal.pone.0069986
- Bruneau, N., and Szepetowski, P. (2011). The role of the urokinase receptor in epilepsy, in disorders of language, cognition, communication and behavior, and in the central nervous system. *Curr. Pharm. Des.* 17, 1914–1923. doi: 10.2174/ 138161211796718198
- Campbell, L. E., Daly, E., Toal, F., Stevens, A., Azuma, R., Karmiloff-Smith, A., et al. (2009). Brain structural differences associated with the behavioural phenotype in children with Williams syndrome. *Brain Res.* 1258, 96–107. doi: 10.1016/j. brainres.2008.11.101
- Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., et al. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* 14:128. doi: 10.1186/1471-2105-14-128
- Chen, H., Jiang, L., Xie, Z., Mei, L., He, C., Hu, Z., et al. (2010). Novel mutations of PAX3, MITF, and SOX10 genes in Chinese patients with type I or type II Waardenburg syndrome. *Biochem. Biophys. Res. Commun.* 397, 70–74. doi: 10.1016/j.bbrc.2010.05.066
- Chen, X. S., Reader, R. H., Hoischen, A., Veltman, J. A., Simpson, N. H., Francks, C., et al. (2017). Next-generation sequencing identifies novel gene variants and pathways involved in specific language impairment. *Sci. Rep.* 7:46105. doi: 10.1038/srep46105
- Chiang, M. C., Reiss, A. L., Lee, A. D., Bellugi, U., Galaburda, A. M., Korenberg, J. R., et al. (2007). 3D pattern of brain abnormalities in Williams syndrome visualized using tensor-based morphometry. *Neuroimage* 36, 1096–1109. doi: 10.1016/j.neuroimage.2007.04.024
- Coe, B. P., Witherspoon, K., Rosenfeld, J. A., van Bon, B. W., Vulto-van Silfhout, A. T., Bosco, P., et al. (2014). Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat. Genet.* 46, 1063–1071. doi: 10.1038/ng.3092
- David, O., Maess, B., Eckstein, K., and Friederici, A. D. (2011). Dynamic causal modeling of subcortical connectivity of language. J. Neurosci. 31, 2712–2717. doi: 10.1523/JNEUROSCI.3433-10.2011
- Donato, F., Rompani, S. B., and Caroni, P. (2013). Parvalbumin-expressing basketcell network plasticity induced by experience regulates adult learning. *Nature* 504, 272–276. doi: 10.1038/nature12866
- Dorus, S., Vallender, E. J., Evans, P. D., Anderson, J. R., Gilbert, S. L., Mahowald, M., et al. (2004). Accelerated evolution of nervous system genes in the origin of Homo sapiens. *Cell* 119, 1027–1040. doi: 10.1016/j.cell.2004.11.040
- Eicher, J. D., Powers, N. R., Miller, L. L., Akshoomoff, N., Amaral, D. G., Bloss, C. S., et al. (2013). Genome-wide association study of shared components of reading disability and language impairment. *Genes Brain Behav.* 12, 792–801. doi: 10.1111/gbb.12085
- Einarsdottir, E., Svensson, I., Darki, F., Peyrard-Janvid, M., Lindvall, J. M., Ameur, A., et al. (2015). Mutation in CEP63 co-segregating with developmental dyslexia in a Swedish family. *Hum. Genet.* 134, 1239–1248. doi: 10.1007/s00439-015-1602-1
- Filice, F., Vörckel, K. J., Sungur, A. Ö., Wöhr, M., and Schwaller, B. (2016). Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism. *Mol. Brain* 9:10. doi: 10.1186/s13041-016-0192-8
- Fisher, S. E. (2017). Evolution of language: lessons from the genome. *Psychon. Bull. Rev.* 24, 34–40. doi: 10.3758/s13423-016-1112-8
- Fox, J. W., Lamperti, E. D., Eksioglu, Y. Z., Hong, S. E., Feng, Y., Graham, D. A., et al. (1998). Mutations in filamin 1 prevent migration of cerebral cortical

neurons in human periventricular heterotopia. Neuron 21, 1315-1325. doi: 10.1016/S0896-6273(00)80651-0

- Gadea, G., and Blangy, A. (2014). Dock-family exchange factors in cell migration and disease. *Eur. J. Cell Biol.* 93, 466–477. doi: 10.1016/j.ejcb.2014.06.003
- Galaburda, A. M., Holinger, D. P., Bellugi, U., and Sherman, G. F. (2002). Williams syndromeneuronal size and neuronal-packing density in primary visual cortex. *Arch. Neurol.* 59, 1461–1467. doi: 10.1001/archneur.59.9.1461
- Graham, S. A., Deriziotis, P., and Fisher, S. E. (2015). Insights into the genetic foundations of human communication. *Neuropsychol. Rev.* 25, 3–26. doi: 10. 1007/s11065-014-9277-2
- Gray, V., Karmiloff-Smith, A., Funnell, E., and Tassabehji, M. (2006). In-depth analysis of spatial cognition in Williams syndrome: a critical assessment of the role of the LIMK1 gene. *Neuropsychologia* 44, 679–685. doi: 10.1016/j. neuropsychologia.2005.08.007
- Hoeft, F., Dai, L., Haas, B. W., Sheau, K., Mimura, M., Mills, D., et al. (2014). Mapping genetically controlled neural circuits of social behavior and visuomotor integration by a preliminary examination of atypical deletions with Williams syndrome. *PLoS One* 9:e104088. doi: 10.1371/journal.pone.0104088
- Horita, H., Kobayashi, M., Liu, W. C., Oka, K., Jarvis, E. D., and Wada, K. (2012). Specialized motor-driven Dusp1 expression in the song systems of multiple lineages of vocal learning birds. *PLoS One* 7:e42173. doi: 10.1371/journal.pone. 0042173
- Horita, H., Wada, K., Rivas, M. V., Hara, E., and Jarvis, E. D. (2010). The dusp1 immediate early gene is regulated by natural stimuli predominantly in sensory input neurons. J. Comp. Neurol. 518, 2873–2901. doi: 10.1002/cne.22370
- Howard, M. L., Palmer, S. J., Taylor, K. M., Arthurson, G. J., Spitzer, M. W., Du, X., et al. (2012). Mutation of Gtf2ird1 from the Williams-Beuren syndrome critical region results in facial dysplasia, motor dysfunction, and altered vocalisations. *Neurobiol. Dis.* 45, 913–922. doi: 10.1016/j.nbd.2011.12.010
- Jackowski, A. P., Rando, K., Maria de Araújo, C., Del Cole, C. G., Silva, I., and Tavares de Lacerda, A. L. (2009). Brain abnormalities in Williams syndrome: a review of structural and functional magnetic resonance imaging findings. *Eur.* J. Paediatr. Neurol. 13, 305–316. doi: 10.1016/j.ejpn.2008.07.002
- Jeong, Y., Leskow, F. C., El-Jaick, K., Roessler, E., Muenke, M., Yocum, A., et al. (2008). Regulation of a remote Shh forebrain enhancer by the Six3 homeoprotein. *Nat. Genet.* 40, 1348–1353. doi: 10.1038/ng.230
- Jernigan, T. L., and Bellugi, U. (1990). Anomalous brain morphology on magnetic resonance images in Williams syndrome and Down syndrome. Arch. Neurol. 47, 529–533. doi: 10.1001/archneur.1990.00530050049011
- Karmiloff-Smith, A., and Mills, D. L. (2006). "Williams Syndrome," in *Encyclopedia of Language and Linguistics*, ed. K. Brown (Oxford: Elsevier) 585–589. doi: 10.1016/B0-08-044854-2/04181-X
- Kimura, R., Swarup, V., Tomiwa, K., Gandal, M. J., Parikshak, N. N., Funabiki, Y., et al. (2018). Integrative network analysis reveals biological pathways associated with Williams syndrome. *J. Child Psychol. Psychiatry* doi: 10.1111/jcpp.12999 [Epub ahead of print].
- Ko, J. M., Lim, B. C., Kim, K. J., Hwang, Y. S., Ryu, H. W., Lee, J. H., et al. (2013). Distinct neurological features in a patient with Schinzel-Giedion syndrome caused by a recurrent SETBP1 mutation. *Childs Nerv. Syst* 29, 525–529. doi: 10.1007/s00381-013-2047-2
- Korenberg, J. R., Chen, X. N., Hirota, H., Lai, Z., Bellugi, U., Burian, D., et al. (2000). Genome structure and cognitive map of Williams syndrome. *J. Cogn. Neurosci.* 12(Suppl. 1), 89–107. doi: 10.1162/089892900562002
- Kos, M., van den Brink, D., Snijders, T. M., Rijpkema, M., Franke, B., Fernandez, G., et al. (2012). CNTNAP2 and language processing in healthy individuals as measured with ERPs. *PLoS One* 7:e46995. doi: 10.1371/journal. pone.0046995
- Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., et al. (2016). Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Res.* 44, W90–W97. doi: 10.1093/nar/ gkw377
- Lalli, M. A., Jang, J., Park, J. H., Wang, Y., Guzman, E., Zhou, H., et al. (2016). Haploinsufficiency of BAZ1B contributes to Williams syndrome through transcriptional dysregulation of neurodevelopmental pathways. *Hum. Mol. Genet.* 25, 1294–1306. doi: 10.1093/hmg/ddw010
- Lauber, E., Filice, F., and Schwaller, B. (2018). Dysregulation of parvalbumin expression in the Cntnap2–/– mouse model of Autism spectrum disorder. *Front. Mol. Neurosci.* 11:262. doi: 10.3389/fnmol.2018.00262

- Lavado, A., Lagutin, O. V., and Oliver, G. (2008). Six3 inactivation causes progressive caudalization and aberrant patterning of the mammalian diencephalon. *Development* 135, 441–450. doi: 10.1242/dev.010082
- Levitin, D. J., Cole, K., Lincoln, A., and Bellugi, U. (2005). Aversion, awareness, and attraction: investigating claims of hyperacusis in the Williamssyndrome phenotype. J. Child Psychol. Psychiatry 46, 514–523. doi: 10.1111/j.1469-7610. 2004.00376.x
- Li, N., and Bartlett, C. W. (2012). Defining the genetic architecture of human developmental language impairment. *Life Sci.* 90, 469–475. doi: 10.1016/j.lfs. 2012.01.016
- Makihara, S., Morin, S., Ferent, J., Côté, J. F., Yam, P. T., and Charron, F. (2018). Polarized dock activity drives Shh-mediated axon guidance. *Dev. Cell* 46:410-425.e7. doi: 10.1016/j.devcel.2018.07.007
- Mariën, P., and Borgatti, R. (2018). Language and the cerebellum. Handb. Clin. Neurol. 154, 181–202. doi: 10.1016/B978-0-444-63956-1.00011-4
- Marjanović, M., Sánchez-Huertas, C., Terré, B., Gómez, R., Scheel, J. F., Pacheco, S., et al. (2015). CEP63 deficiency promotes p53-dependent microcephaly and reveals a role for the centrosome in meiotic recombination. *Nat. Commun.* 6:7676. doi: 10.1038/ncomms8676
- Martens, M. A., Wilson, S. J., and Reutens, D. C. (2008). Research Review: Williams syndrome: acritical review of the cognitive, behavioral, and neuroanatomical phenotype. J. Child Psychol. Psychiatry 49, 576–608. doi: 10.1111/j.1469-7610. 2008.01887.x
- Mervis, C. B., and Becerra, A. M. (2007). Language and communicative development in Williams syndrome. *Ment. Retard. Dev. Disabil. Res. Rev.* 13, 3–15.
- Mervis, C. B., Morris, C. A., Bertrand, J., and Robinson, E. F. (1999). "Williams syndrome: findings from an integrated program of research," in *Neurodevelopmental Disorders*, ed. H. Tager-Flusberg (Cambridge, MA: The MIT Press), 65–110.
- Miyake, F., Kuroda, Y., Naruto, T., Ohashi, I., Takano, K., and Kurosawa, K. (2015). West syndrome in a patient with Schinzel-Giedion syndrome. J. Child Neurol. 30, 932–936. doi: 10.1177/0883073814541468
- Mobbs, D., Eckert, M. A., Menon, V., Mills, D., Korenberg, J., Galaburda, A. M., et al. (2007). Reduced parietal and visual cortical activation during global processing in Williams syndrome. *Dev. Med. Child Neurol.* 49, 433–438. doi: 10.1111/j.1469-8749.2007.00433.x
- Morris, C. A., Mervis, C. B., Hobart, H. H., Gregg, R. G., Bertrand, J., Ensing, G. J., et al. (2003). GTF2I hemizygosity implicated in mental retardation in Williams syndrome: genotype-phenotype analysis of five families with deletions in the Williams syndrome region. *Am. J. Med. Genet.* 123A, 45–59. doi: 10.1002/ajmg. a.20496
- Murdoch, B. (2010). The cerebellum and language: historical perspective and review. *Cortex* 46, 858–868. doi: 10.1016/j.cortex.2009.07.018
- Murphy, E., and Benítez-Burraco, A. (2016). Bridging the gap between genes and language deficits in schizophrenia: an oscillopathic approach. *Front. Hum. Neurosci.* 10:422. doi: 10.3389/fnhum.2016.00422
- Murphy, E., and Benítez-Burraco, A. (2017). Language deficits in schizophrenia and autism as related oscillatory connectomopathies: an evolutionary account. *Neurosci. Biobehav. Rev.* 83, 742–764. doi: 10.1016/j.neubiorev.2016.07.029
- Murphy, E., and Benítez-Burraco, A. (2018). Toward the language oscillogenome. Front. Psychol. 9:1999. doi: 10.3389/fpsyg.2018.01999
- Newbury, D. F., Winchester, L., Addis, L., Paracchini, S., Buckingham, L. L., Clark, A., et al. (2009). CMIP and ATP2C2 modulate phonological short-term memory in language impairment. *Am. J. Hum. Genet.* 85, 264–72. doi: 10.1016/ j.ajhg.2009.07.004
- Nudel, R. (2016). An investigation of NFXL1, a gene implicated in a study of specific language impairment. J. Neurodev. Disord. 8:13. doi: 10.1186/s11689-016-9146-9
- Osório, A., Soares, J. M., Prieto, M. F., Vasconcelos, C., Fernandes, C., Sousa, S., et al. (2014). Cerebral and cerebellar MRI volumes in Williams syndrome. *Res. Dev. Disabil.* 35, 922–928. doi: 10.1016/j.ridd.2013.12.014
- Pääbo, S. (2014). The human condition-a molecular approach. Cell 157, 216–226. doi: 10.1016/j.cell.2013.12.036
- Pagnamenta, A. T., Bacchelli, E., de Jonge, M. V., Mirza, G., Scerri, T. S., Minopoli, F., et al. (2010). Characterization of a family with rare deletions in CNTNAP5 and DOCK4 suggests novel risk loci for autism and dyslexia. *Biol. Psychiatry* 68, 320–328. doi: 10.1016/j.biopsych.2010.02.002

- Paracchini, S., Diaz, R., and Stein, J. (2016). "Advances in dyslexia genetics—new insights into the role of brain asymmetries," in *Advances in Genetics* 96, eds T. Friedmann, J. C. Dunlap, and S. F. Goodwin (London: Academic Press), 53–97.
- Peedicayil, J., and Grayson, D. R. (2018). An epigenetic basis for an omnigenic model of psychiatric disorders. J. Theor. Biol. 443, 52–55. doi: 10.1016/j.jtbi. 2018.01.027
- Pettigrew, K. A., Frinton, E., Nudel, R., Chan, M. T., Thompson, P., Hayiou-Thomas, M. E., et al. (2016). Further evidence for a parent-of-origin effect at the NOP9 locus on language-related phenotypes. J. Neurodev. Disord. 8:24. doi: 10.1186/s11689-016-9157-6
- Phillips, E. A. K., Schreiner, C. E., and Hasenstaub, A. R. (2017). Cortical interneurons differentially regulate the effects of acoustic context. *Cell Rep.* 20, 771–778. doi: 10.1016/j.celrep.2017.07.001
- Pober, B. R., Wang, E., Caprio, S., Petersen, K. F., Brandt, C., Stanley, T., et al. (2010). High prevalence of diabetes and pre-diabetes in adults with Williams syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 154C, 291–298. doi: 10. 1002/ajmg.c.30261
- Purser, H. R., Thomas, M. S., Snoxall, S., Mareschal, D., and Karmiloff-Smith, A. (2011). Definitions versus categorization: assessing the development of lexicosemantic knowledge in Williams syndrome. *Int. J. Lang. Commun. Disord.* 46, 361–373. doi: 10.3109/13682822.2010.497531
- Reilly, J., Klima, E. S., and Bellugi, U. (1990). Once more with feeling: affect and language in atypical populations. *Dev. Psychopathol.* 2, 367–391. doi: 10.1017/ S0954579400005782
- Roll, P., Rudolf, G., Pereira, S., Royer, B., Scheffer, I. E., Massacrier, A., et al. (2006). SRPX2 mutations in disorders of language cortex and cognition. *Hum. Mol. Genet.* 15, 1195–1207. doi: 10.1093/hmg/ddl035
- Roll, P., Vernes, S. C., Bruneau, N., Cillario, J., Ponsole-Lenfant, M., Massacrier, A., et al. (2010). Molecular networks implicated in speech-related disorders: FOXP2 regulates the SRPX2/uPAR complex. *Hum. Mol. Genet.* 19, 4848–4860. doi: 10.1093/hmg/ddq415
- Royer-Zemmour, B., Ponsole-Lenfant, M., Gara, H., Roll, P., Lévêque, C., Massacrier, A., et al. (2008). Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR. *Hum. Mol. Genet.* 17, 3617–3630. doi: 10.1093/hmg/ddn256
- Sakurai, T., Dorr, N. P., Takahashi, N., McInnes, L. A., Elder, G. A., and Buxbaum, J. D. (2011). Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads to increases in social interactions. *Autism Res.* 4, 28–39. doi: 10.1002/ aur.169
- Scharff, C., and White, S. A. (2004). Genetic components of vocal learning. Ann. N. Y. Acad. Sci. 1016, 325–347. doi: 10.1196/annals.1298.032
- Schmitt, J. E., Eliez, S., Bellugi, U., and Reiss, A. L. (2001). Analysis of cerebral shape in Williams syndrome. Arch. Neurol. 58, 283–287. doi: 10.1001/archneur.58. 2.283
- Shao, S., Kong, R., Zou, L., Zhong, R., Lou, J., Zhou, J., et al. (2016). The roles of genes in the neuronal migration and neurite outgrowth network in developmental dyslexia: single- and multiple-risk genetic variants. *Mol. Neurobiol.* 53, 3967–3975. doi: 10.1007/s12035-015-9334-8
- Smith, A. D., Gilchrist, I. D., Hood, B., Tassabehji, M., and Karmiloff-Smith, A. (2009). Inefficient search of large-scale space in Williams syndrome: further insights on the role of LIMK1 deletion in deficits of spatial cognition. *Perception* 38, 694–701. doi: 10.1068/p6050
- Smyth, G. K. (2005). "Limma: linear models for microarray data," in *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*, eds R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, and W. Huber (New York: Springer), 397–420. doi: 10.1007/0-387-29362-0_23
- Stachowiak, M. K., Kucinski, A., Curl, R., Syposs, C., Yang, Y., Narla, S., et al. (2013). Schizophrenia: a neurodevelopmental disorder-integrative genomic hypothesis and therapeutic implications from a transgenic mouse model. *Schizophr. Res.* 143, 367–376. doi: 10.1016/j.schres.2012.11.004
- Sylvester, J. B., Rich, C. A., Loh, Y. H., van Staaden, M. J., Fraser, G. J., and Streelman, J. T. (2010). Brain diversity evolves via differences in patterning. *Proc. Natl. Acad. Sci. U.S.A.* 107, 9718–9723. doi: 10.1073/pnas.100039 5107
- Tassabehji, M., Hammond, P., Karmiloff-Smith, A., Thompson, P., Thorgeirsson, S. S., Durkin, M. E., et al. (2005). GTF2IRD1 in craniofacial development

of humans and mice. Science 310, 1184–1187. doi: 10.1126/science.111 6142

- Tassabehji, M., Read, A. P., Newton, V. E., Harris, R., Balling, R., Gruss, P., et al. (1992). Waardenburg's syndrome patients have mutations in the human homologue of the Pax-3 paired box gene. *Nature* 355, 635–636. doi: 10.1038/ 355635a0
- Thompson, P. M., Lee, A. D., Dutton, R. A., Geaga, J. A., Hayashi, K. M., Eckert, M. A., et al. (2005). Abnormal cortical complexity and thickness profiles mapped in Williams syndrome. *J. Neurosci.* 25, 4146–4158. doi: 10.1523/ JNEUROSCI.0165-05.2005
- Todorovski, Z., Asrar, S., Liu, J., Saw, N. M., Joshi, K., Cortez, M. A., et al. (2015). LIMK1 regulates long-term memory and synaptic plasticity via the transcriptional factor CREB. *Mol. Cell. Biol.* 35, 1316–1328. doi: 10.1128/MCB. 01263-14
- Travis, M. A., van der Flier, A., Kammerer, R. A., Mould, A. P., Sonnenberg, A., and Humphries, M. J. (2004). Interaction of filamin A with the integrin beta 7 cytoplasmic domain: role of alternative splicing and phosphorylation. *FEBS Lett.* 569, 185–190. doi: 10.1016/j.febslet.2004.04.099
- Udwin, O., and Yule, W. (1991). A cognitive and behavioural phenotype in Williams syndrome. J. Clin. Exp. Neuropsychol. 13, 232–244. doi: 10.1080/ 01688639108401040
- Ueda, S., Fujimoto, S., Hiramoto, K., Negishi, M., and Katoh, H. (2008). Dock4 regulates dendritic development in hippocampal neurons. J. Neurosci. Res. 86, 3052–3061. doi: 10.1002/jnr.21763
- Ueda, S., Negishi, M., and Katoh, H. (2013). Rac GEF Dock4 interacts with cortactin to regulate dendritic spine formation. *Mol. Biol. Cell* 24, 1602–1613. doi: 10.1091/mbc.E12-11-0782
- Van Den Heuvel, E., Manders, E., Swillen, A., and Zink, I. (2016). Developmental trajectories of structural and pragmatic language skills in school-aged children with Williams syndrome. *J. Intellect. Disabil. Res.* 60, 903–919. doi: 10.1111/jir. 12329
- Vernes, S. C., Newbury, D. F., Abrahams, B. S., Winchester, L., Nicod, J., Groszer, M., et al. (2008). A functional genetic link between distinct developmental language disorders. *N. Engl. J. Med.* 359:2337. doi: 10.1056/ NEJMoa0802828
- Vias, C., and Dick, A. S. (2017). Cerebellar contributions to language in typical and atypical development: a review. *Dev. Neuropsychol.* 42, 404–421. doi: 10.1080/ 87565641.2017.1334783

- Villanueva, P., Nudel, R., Hoischen, A., Fernández, M. A., Simpson, N. H., Gilissen, C., et al. (2015). Exome sequencing in an admixed isolated population indicates NFXL1 variants confer a risk for specific language impairment. *PLoS Genet.* 11:e1004925. doi: 10.1371/journal.pgen.1004925
- Volterra, V., Capirci, O., Pezzini, G., Sabbadini, L., and Vicari, S. (1996). Linguistic abilities in Italian children with Williams syndrome. *Cortex* 32, 663–677. doi: 10.1016/S0010-9452(96)80037-2
- Wahl, M., Marzinzik, F., Friederici, A. D., Hahne, A., Kupsch, A., Schneider, G. H., et al. (2008). The human thalamus processes syntactic and semantic language violations. *Neuron* 59, 695–707. doi: 10.1016/j.neuron.2008. 07.011
- Whalley, H. C., O'Connell, G., Sussmann, J. E., Peel, A., Stanfield, A. C., Hayiou-Thomas, M. E., et al. (2011). Genetic variation in CNTNAP2 alters brain function during linguistic processing in healthy individuals. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 156B, 941–948. doi: 10.1002/ajmg.b.31241
- Whitehouse, A. J., Bishop, D. V., Ang, Q. W., Pennell, C. E., and Fisher, S. E. (2011). CNTNAP2 variants affect early language development in the general population. *Genes Brain Behav.* 10, 451–456. doi: 10.1111/j.1601-183X.2011. 00684.x
- Xiao, Y., Peng, Y., Wan, J., Tang, G., Chen, Y., Tang, J., et al. (2013). The atypical guanine nucleotide exchange factor Dock4 regulates neurite differentiation through modulation of Rac1 GTPase and actin dynamics. J. Biol. Chem. 288, 20034–20045. doi: 10.1074/jbc.M113.458612
- Xu, C., Aragam, N., Li, X., Villla, E. C., Wang, L., Briones, D., et al. (2013). BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies. *PLoS One* 8:e51674. doi: 10.1371/journal.pone.0051674

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Benítez-Burraco and Kimura. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.